Merck's new mark in HIV
Merck setting up to compete in HIV combo market with Chimerix, Yamasa deals
Merck & Co. Inc. may be positioning itself to compete in the HIV combination therapy market dominated by Gilead Sciences Inc. and ViiV Healthcare LLC, the joint venture of GlaxoSmithKline plc and Pfizer Inc.
While last month's deals get Merck closer to developing a next-generation combination product capable of killing resistant HIV strains, the pharma also appears to have an interest in a second strategy: attacking the reservoirs where the virus is believed to hide from current therapies.
The HIV news is something of a coming-out-again party for Merck, which played a leading role in the discovery of the first wave of HIV drugs decades ago. Although the pharma did win FDA approval for Isentress raltegravir in 2007, and reported $1.4 billion in sales of the HIV integrase inhibitor in 2011, the company had otherwise been largely quiet on the HIV front in recent years after a series of late-stage disappointments.
In the late 1980s, Merck scientists were the first to show that protease inhibition could prevent HIV replication and to publish the crystal structure of HIV protease.
In the 1990s, the company discovered efavirenz,